CROI 2013: Researchers Discuss Advances in Tuberculosis Treatment
- Details
- Category: Tuberculosis (TB)
- Published on Monday, 11 March 2013 00:00
- Written by Keith Alcorn
A new two-drug combination of rifapentine and moxifloxacin can allow tuberculosis (TB) treatment to be taken just once-weekly during the 4-month continuation phase, according to a presentation at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) last week in Atlanta. A related meta-analysis found that rifampicin, a key drug in TB treatment, can be tolerated at much higher levels than used in current clinical practice, suggesting that higher doses might allow the treatment course to be shortened.
Experimental MVA Tuberculosis Vaccine Fails to Protect Infants
- Details
- Category: Tuberculosis (TB)
- Published on Tuesday, 12 February 2013 00:00
- Written by Liz Highleyman
An investigational tuberculosis (TB) vaccine did not provide significant additional protection for babies who were previously immunized with the partially effective standard BCG vaccine, though it did stimulate immune response, researchers reported in the February 4, 2013, advance online edition of The Lancet.
FDA Committee Supports Accelerated Approval of TB Drug Bedaquiline
- Details
- Category: Tuberculosis (TB)
- Published on Friday, 30 November 2012 00:00
- Written by Liz Highleyman
The U.S. Food and Drug Administration (FDA) Anti-Infective Drugs Advisory Committee this week gave a favorable opinion on Janssen's request for accelerated approval of its investigational tuberculosis drug bedaquiline (also known as Sirturo, formerly TMC207) for treatment of multidrug-resistance TB (MDR-TB).
Bedaquiline Approved for Multidrug-resistant Tuberculosis after Long Wait
- Details
- Category: Tuberculosis (TB)
- Published on Thursday, 03 January 2013 00:00
- Written by Liz Highleyman
The U.S. Food and Drug Administration last week approved bedaquiline (brand name Sirturo, formerly TMC207) as part of a combination regimen for adults with multidrug-resistant pulmonary tuberculosis (TB) -- the first approval of a new TB drug in more than 40 years.
WHO: TB Rates Fall, but Drug Resistance Still a Concern
- Details
- Category: Tuberculosis (TB)
- Published on Tuesday, 23 October 2012 00:00
- Written by Press Release
Rates of new tuberculosis (TB) cases and deaths have declined and approximately 20 million people worldwide are alive due to TB care and control efforts, but too little is being done to address multidrug-resistant TB, according to the World Health Organization's Global Tuberculosis Report 2012.
More Articles...
- Adding Delamanid to Combination Regimen Reduces Risk of Death for People with Resistant TB
- Study Shows Extensively Drug-resistant TB is Becoming More Common Worldwide
- ICAAC 2012: Experimental Nitroimidazole TBA-354 Shows Promise against Tuberculosis in Early Studies
- AIDS 2012: No Interactions Seen Between New TB Drug and Popular HIV Meds
Web Design and Development by